<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613844</url>
  </required_header>
  <id_info>
    <org_study_id>HS-18-00291/00984</org_study_id>
    <secondary_id>R01AG054434</secondary_id>
    <secondary_id>GC-201711-2014197</secondary_id>
    <nct_id>NCT03613844</nct_id>
  </id_info>
  <brief_title>DHA Brain Delivery Trial</brief_title>
  <acronym>PreventE4</acronym>
  <official_title>The Delivery of Essential Fatty Acids to the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huntington Medical Research Institutes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer’s Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's
      disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is
      associated with reduced delivery of DHA to the brain. This information will help us identify
      the target population that could benefit from DHA supplementation to prevent cognitive
      decline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Brain DHA Delivery Trial will examine the effect of APOE genotype on the changes of
      cerebrospinal fluid (CSF) DHA to Arachidonic acid (AA) ratio in 160 cognitively healthy older
      individuals in response to DHA supplementation. Randomized clinical trials have yielded mixed
      results on the effect DHA supplementation on cognitive outcomes. This study asks the critical
      question of whether DHA gets into the brain in sufficient amounts after supplementation, and
      whether APOE genotype affects brain penetrance.

      This trial will also test the effect of DHA supplementation on changes in brain structural
      and functional connectivity assessed by MRI, and changes in cognition after two years of
      supplementation in all 320 participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind and randomized placebo controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in cerebrospinal fluid fatty acid levels after the intervention in 160 subjects</measure>
    <time_frame>6 months</time_frame>
    <description>cerebrospinal fluid fatty acids assessed by mass spectrometry</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in functional connectivity using resting state functional MRI in all 320 participants</measure>
    <time_frame>2 years</time_frame>
    <description>Functional Connectivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in structural connectivity using MRI in all 320 participants</measure>
    <time_frame>2 years</time_frame>
    <description>Structural connectivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cognitive measures using the Repeatable Battery for the Assessment of Neuropsychological Outcomes (RBANS) in all 320 participants</measure>
    <time_frame>2 years</time_frame>
    <description>RBANS battery</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in cognitive measures using Cogtrack in all 320 participants</measure>
    <time_frame>2 years</time_frame>
    <description>Cogtrack battery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Brain DHA Delivery and Alzheimer's Disease Risk</condition>
  <arm_group>
    <arm_group_label>DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral DHA supplementation at 2 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for DHA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>DHA supplementation</description>
    <arm_group_label>DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for DHA</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: ≥ 60 and ≤ 80

          -  At least one dementia risk factor (obesity, education years, hypertension,
             hyperlipidemia)

          -  Mini-Mental State Examination (MMSE) ≥ 25

          -  Logical Memory II delayed recall score ≥ 6 and ≤ 18 .

        Exclusion Criteria:

          -  Diagnosis of dementia as assessed by the investigator

          -  Use of omega-3 preparations in the last 3 months

          -  &gt; 200 mg/day of DHA consumption using a validated questionnaire

          -  Use of donepezil, rivastigmine, galantamine and/or memantine

          -  Alcohol or drug abuse

          -  A concomitant serious disease such as active cancer treatment or HIV.

          -  Participation in a clinical trial in the last 30 days

          -  Use of anticoagulants such as Plavix or Coumadin or the newer generation blood
             thinners.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hussein Yassine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabella Cordova, BS</last_name>
    <phone>1-833-872-2724</phone>
    <email>isabella.cordova@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betty Chung</last_name>
    <phone>1-833-872-2724</phone>
    <email>chung@hmri.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussein Yassine</last_name>
      <phone>833-872-2724</phone>
      <email>yasslab@usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017 Mar 1;74(3):339-347. doi: 10.1001/jamaneurol.2016.4899. Review.</citation>
    <PMID>28114437</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Hussein Yassine</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Docosahexaenoic Acids</keyword>
  <keyword>Apolipoprotein E4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>available by request to study principal investigator and after approval by study committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>within 1 year after study publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

